Short Pulse and Q-switched ND-YAG Laser With Topical Carbon Versus Fractional CO2 Laser for Enlarged Facial Pores

NCT ID: NCT04470466

Last Updated: 2020-10-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-19

Study Completion Date

2020-10-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Facial pores are visible topographic features of the skin that reflect openings of pilosebaceous follicles, that may be enlarged causing distress to some individuals. Many patients desire treatment for this condition, which can be an early sign of skin aging. Therapeutic modalities include intense pulsed light, radiofrequency, dermabrasion, oral and topical retinoids, as well as chemical peeling. Lasers, as fractional CO2, short pulse and Q-switched Nd-YAG, can potentially be used in treatment of wide pores.

This study aims at the assessment and comparison of therapy with short pulsed and Q-switched Nd-YAG laser plus topical carbon with fractional CO2 laser in the management of wide facial pores.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

topical carbon cream will be applied to one side of the face in patients with wide facial pores, followed by 2 passes of short pulse 1064 ND:YAG laser, then one pass of Q-switched ND-YAG laser.

fractional CO2 laser will be performed to the other half of the face. the patients will receive 2 treatment sessions

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Lesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

short pulse and Q-switched ND-YAG laser with topical carbon

Group Type ACTIVE_COMPARATOR

short pulse and Q-switched ND-YAG laser with topical carbon

Intervention Type DEVICE

application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face

Fractional CO2 Laser

Group Type ACTIVE_COMPARATOR

fractional CO2 laser

Intervention Type DEVICE

single pass of fractional CO2 laser on the other side of the face

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

short pulse and Q-switched ND-YAG laser with topical carbon

application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face

Intervention Type DEVICE

fractional CO2 laser

single pass of fractional CO2 laser on the other side of the face

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who are more than 18 years old with the large facial pores and are aware of their problem and seeking treatment

Exclusion Criteria

* • Previous laser therapy, chemical peeling, microdermabrasion or cosmetic procedure for the face.

* Patients with any contraindication to laser therapy such as photosensitive diseases, skin malignancies, patients on oral retinoids.
* Keloid-forming tendency.
* Local or systemic treatment for skin pores in the previous 3 months
* Connective tissue disease or the use of immunosuppressive medications.
* Pregnancy.
* Present or past history of herpes labialis.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dina Saadi

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr Alainy

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

las49

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.